N-(2,6-dimethylphenyl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)acetamide;hydrate;hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(2,6-dimethylphenyl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)acetamide;hydrate;hydrochloride
• 化学式: C17H27ClN2O2
• 分子量: 326.9
• InChiKey: QKUBOIZNDHLVLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.86
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  33.3
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• METHOD FOR PREVENTING OR TREATING ARRHYTHMIA, METHOD FOR PREVENTING OR TREATING ATRIAL FIBRILLATION, MODEL OF SUSTAINED ATRIAL FIBRILLATION, METHOD FOR PRODUCING THE MODEL, AND METHOD FOR SCREENING FOR ATRIAL FIBRILLATION INHIBITOR
  申请人：Toho University

  公开号：US20140051756A1

  公开（公告）日：2014-02-20

  A method for preventing or treating atrial fibrillation, including: administering, to an individual, an atrial fibrillation inhibitor containing a compound expressed by one of the following Structural Formulas (I) to (VI) or a pharmacologically acceptable salt thereof: where in the Structural Formula (III), Gluc refers to glucuronic acid,

  预防或治疗心房颤动的方法，包括：向个体施用含有以下结构式（I）至（VI）中的一种化合物或其药理学可接受的盐的心房颤动抑制剂：其中在结构式（III）中，Gluc指的是葡萄糖醛酸。
• MEDICINAL COMPOSITION
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1319399A1

  公开（公告）日：2003-06-18

  A pharmaceutical composition containing a drug (A), a waxy substance (B), and synthetic aluminum silicate and/or hydrous silicon dioxide (C). The invention provides a granular pharmaceutical composition suitable for providing a pharmaceutical characterized in that adhesion of granules thereof onto a granulation apparatus during granulation is minimized and caking of the granules is suppressed.

  一种药物组合物，包含药物（A）、蜡状物质（B）和合成氧化铝硅和/或水合二氧化硅（C）。该发明提供了一种颗粒状药物组合物，适用于提供一种药物，其特点在于在制粒过程中减少颗粒粘附到制粒设备上，并抑制颗粒结块。
• Use of an antidiarrheal for the manufacture of a medicament for the treatment of inflammatory conditions
  申请人：Adolor Corporation

  公开号：EP0937460A2

  公开（公告）日：1999-08-25

  The present invention provides the use of an antidiarrheal for the manufacture of a medicament for the treatment of a pathological condition mediated by TNF production in a mammal, wherein the pathologic condition is an inflammatory one.

  本发明提供了一种止泻药，用于制造治疗哺乳动物体内由 TNF 产生介导的病理状况的药物，其中的病理状况是一种炎症。
• ORAL PREPARATION
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1020193A1

  公开（公告）日：2000-07-19

  An oral administration preparation having excellent taking ability, in which unpleasant tastes of drugs are improved by jointly adding a sugar alcohol having a heat of dissolution of -20 cal/g or less and a pH adjusting agent to the drugs having unpleasant tastes.

  一种具有出色服用能力的口服制剂，通过在有异味的药物中加入溶解热低于-20 cal/g 的糖醇和 pH 值调节剂，可改善药物的异味。
• DISINTEGRATING AGENT
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1048300A1

  公开（公告）日：2000-11-02

  The present invention relates to a disintegrant comprising a substance which is solid at room temperature and has a water solubility of 30 wt.% or more, a saturated aqueous solution of the substance having a viscosity of 50 mPa·s.

  本发明涉及一种崩解剂，其中包含一种在室温下为固体且水溶性为 30 wt.% 或更高的物质，该物质的饱和水溶液的粘度为 50 mPa-s。